CJC-1295 with DAC

Scientific identity. CJC-1295 With DAC is a synthetic GHRH(1-29) analogue incorporating the same four stabilising amino acid substitutions as CJC-1295 No DAC — D-Ala², Aib⁸, Ala¹⁵, and Leu¹⁶ — with an additional Drug Affinity Complex (DAC) modification at Lys³⁰. The DAC consists of a maleimido-propionic acid group conjugated to a lysine residue appended beyond the native 29-residue sequence. In biological systems, the maleimide group undergoes Michael addition with the free thiol of Cys³⁴ on circulating albumin, forming a covalent albumin-peptide conjugate. This albumin-binding mechanism extends the circulating half-life of the peptide from minutes — characteristic of unmodified GHRH analogues — to several days in animal models, shifting the pharmacological profile from pulsatile to sustained GHRHR stimulation.

Primary research target. Growth hormone-releasing hormone receptor (GHRHR) — a class B G protein-coupled receptor expressed predominantly on pituitary somatotroph cells, mediating cAMP-dependent signaling and growth hormone secretion in response to GHRH stimulation.

Research areas: GHRHR pharmacology, albumin-binding peptide research, prolonged GH secretion modelling, pituitary somatotroph biology, GH/IGF-1 axis research, GHRH analogue half-life extension strategies, DPP-IV stability research.

Product quantity: 5mg per vial.

Purity: Greater than 99%, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in human

The DAC Modification

CJC-1295 With DAC carries a maleimido-propionic acid group on a C-terminal lysine. Once in circulation, this maleimide reacts with the free thiol on Cys³⁴ of endogenous albumin, forming a stable thioether bond. Because albumin has a long circulating half-life, this conjugation substantially delays peptide clearance. Animal studies have measured CJC-1295 With DAC plasma half-lives in days rather than minutes — a marked difference from native GHRH and unmodified GHRH(1-29) analogs.

GHRHR Pharmacology

CJC-1295 With DAC shares its core peptide sequence with the No DAC form and acts on the same target: the GHRH receptor (GHRHR), a class B GPCR on pituitary somatotrophs. GHRHR activation drives Gαs-coupled cAMP production, PKA activation, and GH synthesis and secretion. What the DAC modification changes is not receptor selectivity but duration of engagement. Animal studies have characterized sustained, elevated GH and IGF-1 over multi-day periods following administration, in contrast to the transient GH pulses produced by shorter-acting GHRH analogs.

Human Research

CJC-1295 With DAC has been investigated in early-phase human pharmacological studies examining GH and IGF-1 responses in healthy adults. These established proof-of-concept for the albumin-binding half-life extension strategy in humans. The findings concern pharmaceutical-grade compound under controlled trial conditions and do not establish the safety, efficacy, or pharmacokinetic profile of the Longevia Research vial formulation.

Distinction from CJC-1295 No DAC

The two compounds share the same four amino acid substitutions. The sole structural difference is the DAC group. In experimental systems this produces meaningfully different pharmacological profiles: the No DAC form models acute, pulsatile GHRHR stimulation; the DAC form models prolonged receptor engagement. They are separate research tools suited to different experimental questions and should not be treated as interchangeable.

Research Status

CJC-1295 With DAC has no approved therapeutic indication. It has been the subject of early-phase human pharmacological research but has not progressed to approved clinical use. It is supplied for Research Use Only.

Reliable research begins with accurately characterised material. For a DAC-modified 30-residue synthetic peptide such as CJC-1295 With DAC, that means confirming peptide sequence, DAC conjugation integrity, and purity at the batch level — because incomplete DAC conjugation or sequence errors can produce a mixed population of modified and unmodified peptide that confounds pharmacological and half-life experiments.

Purity assessment. Each production lot is characterised to greater than 99% purity by high-performance liquid chromatography (HPLC). Chromatographic purity data is reported on the batch Certificate of Analysis.

Identity confirmation. Peptide identity and DAC modification are confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the DAC-conjugated form. HPLC and LC-MS data together confirm that the material supplied corresponds to the labelled compound at the labelled purity.

Batch traceability and Certificate of Analysis. Every vial of CJC-1295 With DAC 5mg is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information. Researchers evaluating this material for assay work are encouraged to review the current batch documentation before use, since analytical specifications are applied at the lot level.

Handling. This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade modified peptides.

Longevia Research supplies CJC-1295 With DAC 5mg for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

CJC-1295 With DAC is a synthetic albumin-binding research peptide supplied strictly as a research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. No regulatory authority has approved this compound for human or veterinary therapeutic use, and Longevia does not supply it for administration to humans or animals, for clinical diagnostics, or for any therapeutic purpose.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this compound. The scientific literature summarised on this product page describes experimental observations in defined cell-based, animal model, and early-phase human pharmacological systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.